Mirum Pharmaceuticals Q2 sales rise, lifts outlook

Mirum Pharmaceuticals

05/08/2026 21:12

Overview
Rare disease drugmaker's Q2 net product sales rose 38% yr/yr to $176 mln
Company raised 2026 net product sales guidance to $680 mln-$700 mln
Q2 net loss widened to $67 mln as operating expenses increased

Outlook
Mirum raises 2026 net product sales guidance to $680 mln-$700 mln
Company targets NDA submission for volixibat in cholestatic pruritus due to PSC in H1 2027
Topline results from Phase 3 studies for brelovitug expected in Q3 and Q4 2026

Result Drivers
LIVMARLI SALES GROWTH - LIVMARLI net product sales rose 46% yr/yr in Q2, supporting overall sales growth
BILE ACID MEDICINES SALES - Bile Acid Medicines net product sales increased 20% yr/yr in Q2
HIGHER OPERATING EXPENSES - Increased operating expenses, including research and development and licensing costs, contributed to wider net loss

Company press release: ID:nBw7xryQ9a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
 
$176.24 mln
 
Q2 Net Loss
 
$67.23 mln
 
Q2 Operating Expenses
 
$218.78 mln
 
Q2 Operating Income
 
-$42.54 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Mirum Pharmaceuticals, Inc. is $145.00, about 39% above its August 4 closing price of $104.33

Reuters Recommended Reads
Aug 4 - Ultragenyx Q2 revenue rises 28% to record high, net loss narrows
Aug 4 - Travere Therapeutics Q2 product sales rise on FILSPARI demand
Aug 4 - Acadia Pharmaceuticals Q2 revenue rises on DAYBUE STIX demand, lifts 2026 outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)